Akihiro Ko

Form D signer

Akihiro Ko

Chief Executive Officer at Elixirgen Therapeutics

Form D signer

Capital raised by Elixirgen Therapeutics

$8.2M+$4.0M latest round

3 Form D filings · first filed Jan 2025 · Baltimore, MD

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

Elixirgen TherapeuticsBiotech · Baltimore, MDsince Jan 2025

Chief Executive Officer

Signatory on Elixirgen Therapeutics's Form D filings · $8.2M raised across 3

Company filings

via EDGAR · Form D for Elixirgen Therapeutics3

DateCompanyFormAmountRole on filing

Oct 30, 2025Elixirgen TherapeuticsForm D+$4.0MChief Executive Officer

Form DOct 30, 2025 · Elixirgen Therapeutics+$4.0Mas Chief Executive Officer

Mar 31, 2025Elixirgen TherapeuticsForm D+$3.6MChief Executive Officer

Form DMar 31, 2025 · Elixirgen Therapeutics+$3.6Mas Chief Executive Officer

Jan 30, 2025Elixirgen TherapeuticsForm D+$600KChief Executive Officer

Form DJan 30, 2025 · Elixirgen Therapeutics+$600Kas Chief Executive Officer

Overview

Last filing Oct 30, 2025

Akihiro Ko is on file as Chief Executive Officer at Elixirgen Therapeutics in Baltimore, MD. Elixirgen Therapeutics has 3 Form D filings on record, $8.2M raised in total. Akihiro Ko appears as a signatory on the company's filings.

Teammates

Elixirgen Therapeutics · 1

Jeffrey ClelandDirector

Products

Elixirgen Therapeutics · 1

mRNA Therapeutic PlatformRNA Therapeutics

Elixirgen Therapeutics' mRNA platform is at the forefront of developing innovative therapeutics designed to address rare and complex diseases. This platform enables the creation of potent treatments that can potentially modulate genetic expressions to treat conditions effectively.